Table of Contents

Research Articles

• Research Articles

  Differential Expression of Homing Receptor Ligands on Tumor-Associated Vasculature that Control CD8 Effector T-cell Entry

  Amber N. Woods, Ashley L. Wilson, Nithya Srivinisan, Jianhao Zeng, Arun B. Dutta, J. David Peske, Eric F. Tewalt, Randal K. Gregg, Andrew R. Ferguson and Victor H. Engelhard

  Cancer Immunol Res December 1 2017 5 (12) 1062-1073; DOI:10.1158/2326-6066.CIR-17-0190

  
  

  Homing receptor ligands on tumor-associated vasculature were found to vary with anatomical location and depend, in part, on intratumoral effectors. The required homing receptor/ligand interactions were identified that mediate effector CD8⁺ T cell entry into these tumors.
• Research Articles

  Prostate Cancer Cells Express More Androgen Receptor (AR) Following Androgen Deprivation, Improving Recognition by AR-Specific T Cells

  Brian M. Olson, Melissa Gamat, Joseph Seliski, Thomas Sawicki, Justin Jeffery, Leigh Ellis, Charles G. Drake, Jamey Weichert and Douglas G. McNeel

  Cancer Immunol Res December 1 2017 5 (12) 1074-1085; DOI:10.1158/2326-6066.CIR-16-0390

  
  

  Androgen deprivation therapy (ADT), used to treat recurrent prostate cancer, can lead to overexpression of the androgen receptor. ADT combined with vaccination targeted against the androgen receptor led to improved responses in murine prostate cancer models.
• Research Articles

  Natural Killer T-cell Immunotherapy in Combination with Chemotherapy-Induced Immunogenic Cell Death Targets Metastatic Breast Cancer

  Simon Gebremeskel, Lynnea Lobert, Kaitlyn Tanner, Brynn Walker, Tora Oliphant, Livia E. Clarke, Graham Dellaire and Brent Johnston

  Cancer Immunol Res December 1 2017 5 (12) 1086-1097; DOI:10.1158/2326-6066.CIR-17-0229

  
  

  Low-dose cyclophosphamide or gemcitabine treatments, in combination with natural killer T-cell activation therapy, modulated immune function and improved survival in a mouse model of metastatic breast cancer.
• Research Articles

  Interleukin-12 from CD103⁺ Batf3-Dependent Dendritic Cells Required for NK-Cell Suppression of Metastasis

  Deepak Mittal, Dipti Vijayan, Eva M. Putz, Amelia R. Aguilera, Kate A. Markey, Jasmin Straube, Stephen Kazakoff, Stephen L. Nutt, Kazuyoshi Takeda, Geoffrey R. Hill, Nicola Waddell and Mark J. Smyth

  Cancer Immunol Res December 1 2017 5 (12) 1098-1108; DOI:10.1158/2326-6066.CIR-17-0341

  
  

  Several host factors can affect cancer metastasis. Batf3⁺ dendritic cells were shown in mouse models to produce the IL12 that stimulates NK cells to produce IFNγ, which helped to control cancer metastasis.
• Research Articles | AuthorChoice

  Combination of CD40 Agonism and CSF-1R Blockade Reconditions Tumor-Associated Macrophages and Drives Potent Antitumor Immunity

  Karla R. Wiehagen, Natasha M. Girgis, Douglas H. Yamada, Andressa A. Smith, Szeman Ruby Chan, Iqbal S. Grewal, Michael Quigley and Raluca I. Verona

  Cancer Immunol Res December 1 2017 5 (12) 1109-1121; DOI:10.1158/2326-6066.CIR-17-0258

  
  

  This study demonstrates the advantage of combining agonist anti-CD40 with CSF-1R blockade for maximal antitumor benefit and survival in a preclinical mouse model. The results provide rationale for the combination of two distinct immunotherapies to improve clinical outcome.
• Research Articles

  Complex Immune Evasion Strategies in Classical Hodgkin Lymphoma

  Frederik Wein, Marc A. Weniger, Benedikt Höing, Judith Arnolds, Andreas Hüttmann, Martin-Leo Hansmann, Sylvia Hartmann and Ralf Küppers

  Cancer Immunol Res December 1 2017 5 (12) 1122-1132; DOI:10.1158/2326-6066.CIR-17-0325

  
  

  Classical Hodgkin lymphoma uses multiple strategies to evade the immune system. cHL cells promoted regulatory T-cell features in CD4⁺ T cells and invoked additional strategies, such as purinergic signaling, to suppress immune detection.
• Research Articles

  Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy

  Hyunju Lee, F. Stephen Hodi, Anita Giobbie-Hurder, Patrick A. Ott, Elizabeth I. Buchbinder, Rizwan Haq, Sara Tolaney, Romualdo Barroso-Sousa, Kevin Zhang, Hilary Donahue, Meredith Davis, Maria E. Gargano, Kristina M. Kelley, Rona S. Carroll, Ursula B. Kaiser and Le Min

  Cancer Immunol Res December 1 2017 5 (12) 1133-1140; DOI:10.1158/2326-6066.CIR-17-0208

  
  

  Immune checkpoint inhibitor–induced thyroid disorders were assessed in patients with a variety of cancers. Guidance is provided on monitoring and managing thyroid disorders induced by anti–PD-1 monotherapy or in combination with anti–CTLA-4.
• Research Articles

  Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma

  Linda Tran, Clint T. Allen, Roy Xiao, Ellen Moore, Ruth Davis, So-Jin Park, Katie Spielbauer, Carter Van Waes and Nicole C. Schmitt

  Cancer Immunol Res December 1 2017 5 (12) 1141-1151; DOI:10.1158/2326-6066.CIR-17-0235

  
  

  The combination of cisplatin chemotherapy with anti–PD-1/PD-L1 immunotherapy is under investigation in clinical trials. Optimal doses of cisplatin were found to enhance the antitumor immune response, which was further improved by adding anti–PD-1/PD-L1 immunotherapy.
• Research Articles | AuthorChoice

  Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer

  Julia Tchou, Yangbing Zhao, Bruce L. Levine, Paul J Zhang, Megan M. Davis, Jan Joseph Melenhorst, Irina Kulikovskaya, Andrea L Brennan, Xiaojun Liu, Simon F. Lacey, Avery D. Posey Jr., Austin D. Williams, Alycia So, Jose R. Conejo-Garcia, Gabriela Plesa, Regina M. Young, Shannon McGettigan, Jean Campbell, Robert H. Pierce, Jennifer M. Matro, Angela M. DeMichele, Amy S. Clark, Laurence J. Cooper, Lynn M. Schuchter, Robert H. Vonderheide and Carl H. June

  Cancer Immunol Res December 1 2017 5 (12) 1152-1161; DOI:10.1158/2326-6066.CIR-17-0189

  
  

  Transiently expressed chimeric antigen receptor T cells specific for c-Met, expressed in breast cancer, were injected into breast cancer tumors of six patients in a phase 0 clinical trial. Injections resulted in tumor necrosis and were well tolerated.